You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 7,273,928

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,273,928
Title:Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin
Abstract: A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a HLH2 haemocyanin polypeptide and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct further can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecules or construct and recombinant expression product thereof. The invention further relates to a pharmaceutical composition that comprises the expression product of that nucleic acid and antibodies obtainable by immunization of an animal therewith, as well as use of the antibodies in screening methods for the identification of tumors.
Inventor(s): Markl; Jurgen (Gau-Bischofsheim, DE), Altenhein; Benjamin (Wiesbaden, DE), Lieb; Bernard (Mainz, DE), Stiefel; Thomas (Stuttgart, DE)
Assignee: Biosyn Arzneimittel GmbH (Fellbach, DE)
Application Number:11/512,044
Patent Claims:see list of patent claims

Details for Patent 7,273,928

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Biosyn Arzneimittel GmbH (Fellbach, DE) 2019-08-20 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Biosyn Arzneimittel GmbH (Fellbach, DE) 2019-08-20 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Biosyn Arzneimittel GmbH (Fellbach, DE) 2019-08-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,273,928

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.